Islatravir Once Monthly for PrEP Demonstrates Favorable Safety/Tolerability and Meets Pharmacokinetic Threshold Target in Blinded Interim Analysis of Phase IIa Trial

January 27-28 and February 3-4, 2021
Interim analysis showed that islatravir administered once monthly achieved the prespecified pharmacokinetic threshold for predicted HIV pre-exposure prophylaxis efficacy.
Format: Microsoft PowerPoint (.ppt)
File Size: 227 KB
Released: January 30, 2021


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

CCO expert commentary on key studies from HIVR4P // Virtual 2021 on PrEP, implementation strategies, multipurpose prevention technologies, and more

Kenneth Mayer, MD Released: February 25, 2021

Commentary from Dr. Kenneth Mayer on data from HIVR4P 2021 on immunoprophylaxis and multipurpose prevention as PrEP, from Clinical Care Options (CCO)

Kenneth Mayer, MD Released: February 18, 2021

Expert selections of the most important data from HIVR4P 2021 Virtual, including PrEP clinical trials, implementation strategies and more, from CCO

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Kenneth Mayer, MD Released: February 17, 2021

Commentary from Dr. Beatriz Grinsztejn on new data from HIVR4P 2021 on long-acting PrEP islatravir and cabotegravir, from Clinical Care Options (CCO)

Beatriz Grinsztejn, MD, PhD Released: February 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.